Oric Pharmaceuticals (ORIC) Stock Forecast & Price Target

ORIC Pharmaceuticals is supported by a de-risked late-stage story centered on rinzimetostat, whose phase 1b results showed 84% 5-month landmark rPFS in post-abiraterone mCRPC and only 6% grade ≥3 TRAEs, no dose reductions, and no reported secondary malignancies to date. The broader PRC2 thesis is strengthened by external validation from mevrometostat, tazemetostat, and igermetostat, while MEVPRO-1’s shift to 4Q26 is viewed as a potentially positive signal that could validate the mechanism and expand the opportunity beyond the estimated ~17,000 annual US post-abiraterone mCRPC cases. Financially, ORIC ended 2Q26 with about $387.6M in cash, equivalents, and marketable securities, reported a net loss of $0.38 per share, and is expected to have runway into 2H28 while multiple catalysts remain ahead.

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company whose value is heavily dependent on unproven assets, so the biggest fundamental weakness is that ORIC-944, ORIC-114, and ORIC-533 still face binary development, safety, and efficacy risk before any meaningful commercialization can occur. Its outlook is further pressured by regulatory uncertainty and competitive pricing/reimbursement risk, while the cited 35% probability of approval for ORIC-114 and 40% for ORIC-944 underscore how much execution is still needed. Even though it is currently financed and has access to non-dilutive capital, it may still need additional equity funding, which could dilute shareholders, and its 20% workforce reduction in 4Q25 signals a more constrained operating profile.